Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Payables (2016 - 2025)

Historic Payables for INVO Fertility (IVF) over the last 17 years, with Q3 2025 value amounting to $3.3 million.

  • INVO Fertility's Payables fell 4059.57% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 4059.57%. This contributed to the annual value of $8.3 million for FY2024, which is 6267.11% up from last year.
  • As of Q3 2025, INVO Fertility's Payables stood at $3.3 million, which was down 4059.57% from $5.1 million recorded in Q2 2025.
  • In the past 5 years, INVO Fertility's Payables registered a high of $11.3 million during Q1 2025, and its lowest value of $306252.0 during Q2 2021.
  • For the 5-year period, INVO Fertility's Payables averaged around $3.5 million, with its median value being $2.9 million (2023).
  • Per our database at Business Quant, INVO Fertility's Payables skyrocketed by 57425.18% in 2023 and then tumbled by 4059.57% in 2025.
  • INVO Fertility's Payables (Quarter) stood at $896828.0 in 2021, then surged by 135.46% to $2.1 million in 2022, then surged by 141.24% to $5.1 million in 2023, then surged by 62.67% to $8.3 million in 2024, then plummeted by 60.53% to $3.3 million in 2025.
  • Its Payables stands at $3.3 million for Q3 2025, versus $5.1 million for Q2 2025 and $11.3 million for Q1 2025.